Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.
UAA201015130A2008-06-172009-06-16Glucagon/glp-1 receptor co-agonists for the treatment of metabolic disorder and obesity
UA104000C2
(en)
Use of an alpha-7 nicotinic acetylcholine receptor agonist for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's disease.